SEC Form 4 · accession 0001140361-19-002080
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Nolan
Officer — Chief Business Officer
Period of report
Jan 30, 2019
Accepted (ET)
Jan 31, 2019 · 7:48 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 30, 2019 | P | 20,000 | $0.648 | A | 21,625 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price of $0.648 per share represents a weighted average of purchase prices ranging from $0.635 to $0.650 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price